RTTNews回顾5只过去大涨的生物科技/医疗股，无新增公司级催化

5 Stocks That Created Fortunes: CMPS +327%, ARWR +222%, CGON +148%, DRTS +182%, ELMD +86%
Business
Latest Headlines
Top Stories
Breaking News
Earnings
Biotech
Investors
Stock Alerts
IPOs
M&A
Canadian
UK
Wallstreet Events
Industry News
Technology
Software
Banking
Automotive
Energy
More
Corp. Calendars
Dividends
Stock Splits
Buybacks
Conference Calls
Earnings Calendar
Pos Pre-announcements
Profit Warnings
Positive Surprise
Negative Surprise
Latest Earnings
FDA Calendars
Drug Approvals
Clinical Trial Calendar
Ratings Changes
Upgrades
Downgrades
Cov Initiations
Cov. Reiterated
Economy
Economic News
US
Europe
Asia
Global
Economic Calendar
Economic Scorecard
Cryptocurrency
Crypto
Blockchain
Markets
Morning Mkt Analysis
US Commentary
European Commentary
Asian Commentary
Canadian Commentary
Indian Commentary
Commodities
Bonds
Currencies
Politics
World
White House
Elections
General News
Forex
FX Top Stories
Currency Analysis
Currency Alerts
Health
Coronavirus
COVID-19 Calendar
Diet & Fitness
Cannabis
Kids Health
Men's Health
Women's Health
Cancer News
Drug Development
Mental Health
Slide Shows
Entertainment
Music news
Pop
Rock
Classic Rock
Rap/Hip-Hop
Country
Alternative
Oldies
All Genre
Content Licensing
Newswires & Feeds
Content Syndication
Digital Signage Services
Radio News Services
Premium Services
Premium
Intelligent Investor
Biotech Investor
NEW
Login
Latest News Videos
Free Content
RSS Feeds
Press Releases
Search
Contact Us
Corp. News
Market News
Health News
Entertainment News
Music News
TODAY'S TOP STORIES
By
Prabha Kurup
✉
|
Published:
7/27/2026 6:13 AM ET
Follow Us
Join Us
Add
as your preferred news source on Google
Add Now
"If you aren't willing to own a stock for 10 years, don't even think about owning it for 10 minutes." - Warren Buffett. The Oracle of Omaha's timeless advice reminds us that patience is one of the key principles of investing.
The following are some of the investment ideas we featured on our website that went on to deliver impressive returns in less than two years. Were these stocks in your portfolio?
Arrowhead Pharmaceuticals Inc. (
ARWR
)
Arrowhead Pharma is a commercial-stage biotechnology company developing RNA interference (RNAi)-based medicines designed to silence disease-causing genes and treat intractable diseases. Its lead drug Redemplo is indicated as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia. In the U.S., the drug was approved last November.
Report Published:
September 15, 2025
What's Driving the Stock?
•
FDA approval
of Redemplo in the U.S. in November 2025
• Approval of Redemplo in Canada in January 2026
• Encouraging interim results from two Phase 1/2a clinical trials of ARO-INHBE and ARO-ALK7, the company's investigational RNA interference (RNAi) therapeutics being developed as potential treatments for obesity in January 2026.
• Approval of Redemplo in China in January 2026, triggering a $10 million milestone payment from Sanofi.
• Receipt of positive CHMP Opinion recommending approval of Redemplo in Europe in April 2026.
• Approval of Redemplo by the European Medicines Agency in June 2026.
• Topline results from the global Phase 3 SHASTA-3 and SHASTA-4 clinical studies of Redemplo in patients with severe hypertriglyceridemia (sHTG) in July 2026.
Potential Catalysts
• A supplemental new drug application for Redemplo is expected to be submitted to the FDA before the end of 2026.
• Financial results for the fiscal 2026 third quarter ended June 30, 2026, are expected to be reported on August 4, 2026.
Stock Performance Since Publication
• Published Date: September 15, 2025
• Published Price: $29.70
• 52-week High: $95.49 (+222%) on July 22, 2026
• Current Price: $85.60 (+182%) on July 24, 2026
COMPASS Pathways plc (
CMPS
Compass Pathways is a biotechnology company focused on improving mental
health
treatment through innovative, evidence-based therapies. COMP360, its lead investigational synthetic psilocybin therapy, is in a Phase 3 program for treatment-resistant depression, which includes two trials, COMP005 and COMP006.
April 23, 2025
• Strategic collaboration with HealthPort, a multi-site comprehensive community health organisation, established on April 29, 2025.
• Positive Phase 3 COMP005 trial results in treatment-resistant depression reported in June 2025. The 6-week primary endpoint of a highly statistically significant and clinically meaningful reduction in symptom severity was achieved.
• FDA acceptance of Investigational New Drug (IND) application for COMP360 in January 2026, enabling the initiation of a late-stage clinical trial in patients with PTSD.
• Positive Part A data from the Phase 3 COMP006 trial of COMP360 in treatment-resistant depression were reported in February 2026.
• FDA granted Compass NDA rolling review request and selected COMP360 for the Commissioner's National Priority Voucher (CNPV) program for treatment-resistant depression in April 2026.
• 26-week (Part B) data from Phase 3 COMP006 trial of COMP360 reported in July 2026.
Potential Catalyst
• The final NDA submission of COMP360 in treatment-resistant depression remains on track for Q4, 2026.
• Published Date: April 23, 2025
• Published Price: $3.61
• 3.5-year High: $15.40 (+327%) on June 29, 2026
• Current Price: $11.26 (+212%) on July 24, 2026
CG Oncology Inc. (
CGON
CG Oncology is a late-stage clinical biopharmaceutical company developing medicines for bladder cancer. Its lead drug candidate is Cretostimogene in Phase 3 development for Non-Muscle Invasive Bladder Cancer.
April 28, 2025
• Positive data from Phase 3 BOND-003 Cohort C study presented in April 2025. In the BOND-003 Cohort C study, Cretostimogene monotherapy was evaluated in high-risk Non-Muscle Invasive Bladder Cancer unresponsive to Bacillus Calmette Guerin (BCG) therapy with carcinoma in situ (CIS) with or without Ta or T1 disease.
• Positive first results from Cohort CX of CORE 008, a Phase 2 study of Cretostimogene in combination with gemcitabine sequential versus concurrent treatment schedules in patients with high-risk (HR) non-muscle invasive bladder cancer reported in May 2026.
• PIVOT-006 Phase 3 topline data evaluating Cretostimogene monotherapy for intermediate-risk NMIBC expected in 1H 2026.
• Phase 3 BOND-003 Cohort C long-term data expected in 2026.
• Updated results from Cohort A of Phase 2 CORE 008 trial anticipated in the second half of 2026.
• Phase 2 CORE-008 Cohort CX topline data expected in 2026.
• Published Date: April 28, 2025
• Published Price: $31.00
• All-time High: $77.00 (+148%) on June 30, 2026
• Current Price: $69.32 (+124%) on July 24, 2026
Alpha Tau Medical Ltd. (
DRTS
Alpha Tau is an Israeli oncology therapeutics company developing alpha-radiation cancer therapy Alpha DaRT for the treatment of solid tumors.
December 11, 2025
• First pre-market approval module to the FDA for Alpha DaRT for the treatment of recurrent cutaneous squamous cell carcinoma was submitted in January 2026.
• Final results from its first-in-human pancreatic cancer study in Montreal, Canada, exploring the use of Alpha DaRT in treating pancreatic ductal adenocarcinoma released in January 2026.
• The FDA approved Investigational Device Exemption supplement to expand Alpha DaRT IMPACT trial to patients with pancreatic cancer receiving gemcitabine with Abraxane in April 2026.
• Promising updated pooled results from two first-in-human clinical trials of Alpha DaRT in pancreatic ductal adenocarcinoma presented in May 2026.
• Completion of enrollment in ReSTART pivotal trial, a U.S. multicenter study of intratumoral Alpha DaRT for the treatment of patients with recurrent cutaneous squamous cell carcinoma in May 2026.
• Promising interim results from REGAIN, the U.S. Alpha DaRT trial in recurrent glioblastoma, reported in May 2026, demonstrated 100% local disease control, a 67% complete response rate, and a favorable safety profile in patients treated to date.
• Strategic collaboration agreement with Tolmar International Ltd., a commercial player in the U.S. urology, oncology, endocrinology and pediatric endocrinology
markets
, to develop and commercialize Alpha DaRT for the treatment of prostate cancer in the United States signed in June 2026.
• Positive results from a clinical study evaluating Alpha DaRT in combination with Merck's Keytruda in elderly patients with locally advanced and metastatic head and neck squamous cell carcinoma reported in July 2026.
• Top-line data from ReSTART pivotal U.S. multi-center trial in recurrent cutaneous squamous cell carcinoma expected around the end of 2026.
• Initial data from the IMPACT pancreatic cancer pilot study in the U.S. targeted for late 2026 or early 2027.
• Published Date: December 11, 2025
• Published Price: $5.00
• 52-week High: $14.11 (+182%) on July 6, 2026
• Current Price: $12.50 (+150%) on July 24, 2026
Electromed Inc. (
ELMD
Electromed is a commercial-stage medical device company that focuses on products that provide airway clearance therapy, including the SmartVest Airway Clearance System, to patients with compromised pulmonary function.
November 10, 2025
• Strong quarterly results, with year-over-year growth in both revenue and profit.
• The company is expected to report financial results for the three months ("Q4 FY 2026") and the full year ended June 30, 2026, during the last week of next month.
• Published Date: November 10, 2025
• Published Price: $25.47
• 52-week High: $47.40 (+86%) on July 7, 2026
• Current Price: $38.41 (+51%) on July 24, 2026
Related Reading
5 Undervalued Stocks That Soared: SION +277%, FBRX +306%, NKTR +869% & More
Returns Matter: NUTX +214%, CORT +145%, GKOS +97% - Were These Biotech Stocks In Your Portfolio?
5 Biotech Stocks That Delivered 100% To 300% Gains: Did Your Winning Trades Offset Portfolio Losses?
5 Biotech Stocks That Skyrocketed 105% To 235% — TWST, INDV, MIRM & More
6 Biotech Stocks That Delivered Stunning Gains: INBX +700%, PVLA +500%, MBX +300%, ABSI +200% & More
5 Biotech Stocks That Delivered Triple-Digit Gains - SYRE Up 400%, BFLY Up 300% & More
For comments and feedback contact: editorial@rttnews.com
Business News
Biotech Stocks Facing FDA Decision In July 2026
Biotech Stocks Facing FDA Decision In June 2026
Biotech Stocks Facing FDA Decision In May 2026
Latest Updates on Middle East War
U.S. Dollar Ticks Higher As U.S. Steps Up Threats On Iran While Crude Oil Prices Plunge
July 24, 2026 17:00 ET
Canadian Stocks Advance As Trump Intensifies Pressure On Iran, Announces New Tariffs
July 24, 2026 16:34 ET
Crude Oil Plummets Amid OPEC's Decision To Increase Output, Profit Taking
July 24, 2026 14:44 ET
U.S. Dollar Advances As Soaring Crude Oil Prices, US Labor Department Data
July 23, 2026 17:00 ET
Gold Advances Amid Crude Oil Plunge Ahead Of Upcoming U.S. Fed Rate Meeting
July 24, 2026 13:39 ET
View More
Global Economics Weekly Update - July 20 – July 24, 2026
July 25, 2026 02:46 ET
The latest policy decision from the European Central Bank dominated the scene this week that was relatively slow for economics news flow. In the U.S., main highlights were the weekly initial jobless claims and new home sales data. In Europe, the ECB rate decision and the latest inflation figures from the U.K. drew attention. In Asia, results of a private sector survey from India were in focus.
View More Videos
RELATED NEWS
Arrowhead Pharma Stock Jumps 24% On Positive Phase 3 Plozasiran Trial Results
Latest Updates on COVID-19
KFF Poll Finds AI Health Chatbot Users More Likely To Believe Vaccine Myths
July 01, 2026 14:27 ET
Editor's Pick
Most Read
Most Emailed
AstraZeneca Q2 Pre-tax Profit Down, But EPS Rise; Backs Positive FY26 View
July 27, 2026 04:19 ET
Verizon Lifts FY26 View Despite Weak Q2, Expands Buyback To Up To $4.5 Bln; Shares Up
July 24, 2026 10:21 ET
EU Commission Flags TikTok's Minor Account Safety Gaps
July 24, 2026 09:56 ET
Volkswagen Cuts FY26 Revenue View After Weak Q2 Profit, Volume
July 24, 2026 05:33 ET
T-Mobile US Q2 Profit Edges Up, Net Additions Drop, Backs FY26 View; Stock Down
July 23, 2026 09:43 ET
GE Vernova Q2 Profit, Orders Climb; Backs FY26 Margin View, Lifts Revenue Forecast; Stock Down
July 22, 2026 07:33 ET
AT&T Reiterates FY26 Outlook - Update
July 22, 2026 07:02 ET
OpenAI Says Advanced AI Models Escaped Test Environment In Cybersecurity Incident
July 22, 2026 17:46 ET
WSP Raises Arcadis Acquisition Offer To €51.50 After Initial Rejection
July 24, 2026 11:50 ET
Union Pacific Signs MoU With CN Supporting Proposed Norfolk Southern Merger
July 23, 2026 01:19 ET
Amapá Minerals Reveals Pricing Of IPO Of 127.27 Mln Common Shares At $1.10/Shr
July 24, 2026 01:42 ET
ATOSS H1 Profit Rises On Higher Revenue; Maintains FY26, FY27 Forecast
July 24, 2026 02:41 ET
Eligible Amazon Prime Members Have Until July 27 To Claim Up To $51 In FTC Settlement
July 24, 2026 17:15 ET
Safety Insurance To Be Acquired By Mapfre In $1.54 Bln All-Cash Deal
July 23, 2026 17:11 ET
Nestlé SA H1 Profit Declines, Confirms FY26 Outlook
July 23, 2026 02:21 ET
Dassault Aviation H1 Profit Jumps; Reaffirms 2026 Sales Outlook
July 22, 2026 13:55 ET
JD Sports Fashion Appoints Darren Shapland As Interim Chair
July 22, 2026 00:36 ET
Moncler Reports Higher Revenue In H1 Amid Board Changes
July 22, 2026 14:00 ET
LG Display Q2 Operating Loss Narrows, Turns To Profit In H1; Stock Gains
July 22, 2026 00:54 ET
Alstom Q1 Sales Rise, Confirms FY27 Outlook
July 22, 2026 14:01 ET
V-ZUG Holding Ltd H1 Profit Rises
July 22, 2026 00:57 ET
Gecina Reports H1 Consolidated Net Loss Despite Higher Recurrent Earnings
July 22, 2026 14:19 ET
GEA Group Q2 Preliminary Sales Improve
July 22, 2026 00:58 ET
Valeo H1 Net Income Rises, Reaffirms FY26 Sales Outlook
Lonza H1 Results Climb, Lifts FY26 CORE EBITDA Margin View, Backs Sales Growth Forecast
July 22, 2026 01:15 ET
Valeo S.A. H1 Sales Decline
July 22, 2026 15:54 ET
VAT Group Agrees To Acquire Atonarp For CHF 110 Mln
July 22, 2026 01:16 ET
Editors Pick
Loading...
Copyright © 2026 RTTNews. All rights reserved.
By using this site, you agree to the
Terms of Service
.
About Us
Privacy
Sitemap